Contra-indicated in active hepatitis B virus infection.
Immune-mediated colitis, which can present as a severe and acute-onset form of colitis, has been reported in patients receiving ocrelizumab in the postmarketing setting. Some cases of colitis were serious, requiring hospitalization, with a few patients requiring surgical intervention. Systemic corticosteroids were required in many of these patients. The time from treatment initiation to onset of symptoms in these cases ranged from a few weeks to years. Monitor patients for immune-mediated colitis during ocrelizumab treatment, and evaluate promptly if signs and symptoms that may indicate immune-mediated colitis, such as new or persistent diarrhea or other gastrointestinal signs and symptoms, occur.
- TRADE NAME: Ocrevus (Genentech)
- INDICATIONS: Relapsing or primary progressive forms of multiple sclerosis
- CLASS: CD20-directed cytolytic monoclonal antibody, Monoclonal antibody
- HALF-LIFE: 26 days
- FDA APPROVAL DATE: 03/28/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: May cause fetal toxicity based on findings in animal studies
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/21/2025
